While it has been shown that the primary motor cortex (M1) receives dopaminergic projections, the functional role of these projections is poorly characterized. Here, it is hypothesized that dopaminergic signals modulate M1 excitability and somatotopy, two features of the M1 network relevant for movement execution and learning.
Dopaminergic modulation of motor maps in rat motor cortex: an in vivo study Abstract While the primary motor cortex (M1) is know to receive dopaminergic projections, the functional role of these projections is poorly characterized. Here, it is hypothesized that dopaminergic signals modulate M1 excitability and somatotopy, two features of the M1 network relevant for movement execution and learning. To test this hypothesis, movement responses evoked by electrical stimulation using an electrode grid implanted epidurally over the caudal motor cortex (M1) were assessed before and after an intracortical injection of D1-(R-(+),8-chloro,7-hydroxy,2,3,4,5,-tetra-hydro,3-methyl,5-phenyl,1-H,3-benzazepine maleate, SCH 23390) or D2-receptor (raclopride) antagonists into the M1 forelimb area of rats. Stimulation mapping of M1 was repeated after 24 h. D2-inhibition reduced the size of the forelimb representation by 68.5% (P<0.001). Movements thresholds, i.e., minimal currents required to induce movement responses increased by 37.5% (P<0.001), and latencies increased by 35.9% (P<0.01). Twenty-4 h after the injections these effects were reversed. No changes were observed with D1-antagonist or vehicle. By enhancing intracortical excitability and signal transduction, D2-mediated dopaminergic signaling may affect movement execution, e.g. by enabling task-related muscle activation synergies, and learning.
Introduction
The neocortex receives dopaminergic projections via the mesocortical pathway from the ventral tegmental and adjacent areas containing dopaminergic neurons (Seamans and Yang, 2004; Smythies, 2005) . Rostral regions of cortex receive denser dopaminergic projections than caudal regions, but for both, primates (Williams and Goldman-Rakic, 1993) and rodents (Berger et al., 1991) , dopaminergic projections to primary motor cortex (M1) were demonstrated. Dopamine (DA) acts through two biochemically and pharmacologically characterized families of receptors (Civelli et al., 1993) . D1 receptors (D1a, D5) stimulate adenylate cyclase thereby increasing intracellular cyclic 3'-5'-AMP (cAMP) levels (Kebabian and Calne, 1979) .
In contrast, D2 receptors (D2, D3, D4) inhibit adenylate cyclase (Onali et al., 1984) . Both types of receptors are present in the rodent and primate neocortex and show inhomogeneous distribution across cortical layers. D1 receptors are present in superficial (layer I, II, IIIa) and deep (V and VI) layers (for rodents: Savasta et al., 1986 ; for primates: (Lidow et al., 1991) ).
D2 receptors are expressed primarily in layer V but tenfold less than D1 (for rodents : Ariano et al., 1993; for primates: Lidow et al., 1991) . Additionally, different types of cortical neurons show different DA receptor expression profiles (Williams and Goldman-Rakic, 1993; Bergson et al., 1995 , Gorelova et al., 2002 . In rat prefrontal cortex and M1, co-localization of both subtypes were observed in layer V/VI pyramidal cells (Awenowicz and Porter, 2002) .
Although it seems plausible that dopaminergic input modulates motor function, its physiological role is still poorly defined. Depletion of M1 dopaminergic terminals by intracortical injection of 6-hydroxydopamine did not impair performance of a skilled reaching task (Whishaw et al., 1992) . It may be that motor cortical DA has a specific role in movement learning (Pekanovic et al., 2007; Rioult-Pedotti et al., 2007) . On the cellular level, partially contradictory information exists on the effects of DA on network activity (reviewed by Seamans and Yang, 2004; Smythies, 2005) . Information on how DA affects motor cortical network activity is necessary to understand its role for behaviour.
The objective here is to investigate how DA affects motor cortical excitability and somatotopy. Both are features of M1 that play important roles for motor function and learning (Pascual-Leone et al., 1995; Nudo et al., 1996; Monfils et al., 2005; Molina-Luna et al., 2008) .
Experimental procedures Animals and experiments
Seventeen male Long-Evans rats (8-10 weeks, 250-350g) were included in this study.
Animals were housed individually in a 12/12-hr light/dark cycle. After electrode implantation, animals were allowed to recover for five days. Stimulation mapping was performed at baseline (session 1 "base"), 30min after intracortical microinjection of DA antagonists (session 2 "injection"), and after 24 hours (mapping session 3 "recovery"). Each session lasted 1.5 -2 hours. Between sessions 2 and 3, animals were returned to their home cages.
Surgical procedures
A thin-film polyimide-based microelectrode array was implanted epidurally together with a cannula for intracortical drug application. The electrode array, surgical procedures and the stimulation technique were described previously (Molina-Luna et al., 2007 and 2008) . In brief, a craniotomy over the right hemisphere was performed (coordinates for the motor cortex with respect to Bregma; 4 mm posterior, 5 mm anterior, 5 mm lateral, 2 mm medial) under ketamine/xylazine (70/10mg/kg i.p.) anaesthesia. The electrode array was placed over the caudal motor cortex. The guide cannula (15mm long, Unimed SA, Lausanne, Switzerland)
was slowly inserted through a preformed hole in the polyimid-matrix of the array to a depth of 900 µm and protected with an obturator. Positioning of the array in the middle of the craniotomy ensured that the hole came to lie close to the centre of the forelimb representation in the right M1 (2 mm anterior and 2 mm lateral with respect to bregma). The cannula hub and the array's connector plugs were anchored onto the rats' skull with screws and bone cement. 
Epidural stimulation and drug application
For stimulation mapping, animals were sedated with 40-50 mg/kg i.p. ketamine.
Stimulation was started when whisker tremors of small amplitude, typical for ketamine anaesthesia of superficial to medium depth were observed (Kisley and Gerstein, 1999) . The stimulation procedure was performed as previously described (Molina-Luna et al., 2007 and 2008) . Briefly, biphasic stimuli consisting of constant current pulses (100 stimuli in 300 Hz, constant current of +/-1-4.8mA, per electrode) were routed serially to contacts in random order. During mapping, the animal was suspended in a sleeve with the limbs hanging freely to allow for recording (via acceleration sensors attached to each limb) and observation (video footage) of evoked limb movements. Using these video recordings, the primary joint (distal forelimb including wrist and elbow, proximal forelimb including shoulder and neck and hindlimb including foot and knee) involved in evoked movement was determined. For confirmation, the magnitude of the acceleration sensor signal was utilized as a metric to compare different limbs (Molina-Luna et al., 2008) . For each contact, an evoked movement was only considered if it was verified, i.e., after a movement response was obtained, the stimulation current was decreased until the response disappeared and then increased again until the response reappeared or a maximum of 4.8 mA was reached. In the latter case, the response was not verified and the contact was considered non-responsive. The stimulus intensity required to verify a movement response was considered as the motor threshold.
Response latency was the time between the stimulus and the first deflection of the accelerometer signal.
To test the effect of D1-and D2 receptor antagonization, rats received intracortical 
Data Analysis
Analyses were performed using Statistica version 7.0 (StatSoft Inc., Tulsa, OK, USA) and MatLab (Version 7, The MathWorks Inc., Natick, MA, USA). The size of a representation was quantified by the number of responsive contacts per limb or joint. The representation area in mm² can be obtained by multiplying the number of contacts with 0.48. If a contact was dysfunctional due to manufacturing defects or damage during implantation (mean of 1.27±0.07 positions per experiment, constant across mapping sessions), the missing value was estimated by the average of the neighbouring contacts. Motor maps were visualized using SigmaPlot (Version 10.9, SPSS Inc., Chicago, Illinois, USA). Repeated measures analysis of variance was performed with group (SCH23390, raclopride or saline) and joint (distal forelimb, proximal forelimb and hindlimb) as between subjects factors, time (three time points) as within-subjects factor and the interaction of group x time x joint. Baseline map size was entered as a continuous covariate in the model to avoid false positive results caused by baseline differences. The sphericity assumption was tested using the Mauchly criterion. If this test was significant, Greenhouse-Geisser correction was used. Post hoc tests were performed using Bonferroni correction for multiple comparisons. Neck and whisker movement were not included in the analyses because they were infrequently and less accurately detected (absence of acceleration sensors). Paired student's t-tests were used to compare spatial distances towards the injection site. Numerical results are expressed as mean and SEM.
Histological assessment of brain injury
The brains were evaluated for signs of tissue damage and for verification of guide cannula placement. Coronal sections (50µm) were Nissl-stained and inspected using a microscope (x10 and x40 magnification) (Figure 1) .
Results

Effects of DA antagonists on representation size
At baseline, the number of responsive contacts as a measure of representation size was not different between groups (p=0.45).
The size of the distal forelimb representation shrunk after injection of the D2 antagonist raclopride (n=6) but not after the administration of the D1-receptor antagonist SCH 23390 (n=6) or vehicle (n=5) and recovered 24h later (Figure 2 and 3 ). In the model predicting representation size, the interaction between group x time x joint was significant (F(8,70)=6.3 p<0.001). Therefore, separate models were computed for each joint. For distal forelimb but not for proximal forelimb or hindlimb, we found a significant group x time interaction (F=(4,70)=9.4, p<0.001). For the distal forelimb, post-hoc analysis revealed a decrease of responsive contacts after raclopride injection (map 1: 16.8±3.1 contacts -map 2:
5.3±0.7 contacts; p<0.001), which was reversible after one day of recovery (map 3: 16.0±3.1 contacts; p<0.001).
Effects of DA antagonists on stimulation thresholds
At baseline, stimulation threshold as a measure of cortical excitability did not differ between groups (p=0.35).
Motor thresholds for all joints increased after the injection of raclopride and recovered after 24h. D1-receptor antagonist or vehicle injections had no effect ( Figure 4A ). In the model predicting stimulation thresholds, the interaction between group x time was significant (F(4,54)=2.9, p=0.029). The interaction between group x time x joint (p=0.8) as well as the main effect of joint (p=0.96) were insignificant and the variable joint was dropped from the model. For the raclopride group, post-hoc analysis showed a significant increase in stimulation thresholds after injection (map 1: 1.6±0.1mA -map 2: 2.2±0.2mA; p<0.001), which was reversible after 24h of recovery (map 3: 1.7±0.3 mA p<0.001, Figure   4A ).
Effects of DA-antagonists on movement latencies
At baseline the shortest latencies were observed for proximal forelimb (57.96±6.79 ms), followed by distal forelimb (wrist/elbow; 85.29±6.01 ms) and hindlimb (171.77±12.65 ms; effect of joint on latency: F(2, 24)=32.92, p<0.001). The group factor did not influence the latency at baseline (p=0.67).
D2-antagonist injections prolonged the latency. The effect was reversed at 24 hours.
D1-antagonist or vehicle had no effect ( Figure 4B and C) . In the model predicting latency, the group x time interaction was significant (F(4,46)=5.62, p<0.001). The interaction between group x time x joint (p=0.28) as well as the main effect of joint (p=0.4) were insignificant and the variable joint was dropped from the model. Post hoc analysis revealed a significant increase in latencies after raclopride injection (map 1: 108.7±13.4 ms -map 2: 147.3±20.9 ms; p=0.008) and a consecutive decrease after 24h (map 3: 99.7±14.1 ms p=0.006).
Cannula placement
The center of the wrist/elbow representation was closer to the injection site (1.9 ± 0.09 mm) than the hindlimb (2.24±1.6 mm; paired t-test: p=0.021) and the shoulder/neck representation (2.11±2.0 mm; paired t-test: p=0.05). Intracortical placement of the guide cannula was verified histologically for all 17 animals. Except for the cannula tract, no further signs of cortical injury or scar formation were observed (Figure 1) .
Discussion
Only 
D2 receptor specificity
In contrast to D2, the D1 antagonist did not affect cortical excitability or evoked response latencies. This is surprising, because D1 receptors are more abundant in M1 (Lidow et al., 1991) and often have counteracting effects due to their opposite action on adenylate cyclase (Seeman and Van Tol, 1994) . But as argued by Seamens and Yang (2004) , the effects of dopaminergic modulation critically depend on (1) the cortical layer where modulation takes place, (2) concentrations of DA or antagonists and (3) the experimental timeline.
Regarding 1, the vertical intracortical spread of the drug covers all cortical layers as shown previously using India ink injection using the identical injection technique (Luft et al., 2004) . Hence, a bias due to a inhomogeneous distribution across cortical layers is unlikely.
Regarding 2, while at low concentrations DA predominantly acts via D1 receptors, D2
receptor activation requires higher DA concentrations (Trantham-Davidson et al., 2004) .
When present in such high concentrations, DA does act as a partial D1 receptor antagonist (Seamans and Yang, 2004) . So far, no measurements of DA concentrations in M1 have been performed. However, repetitive high-frequency stimulation (here: 300 Hz; 100 pulses) at increasing stimulation intensities may reach -at least in the synaptic cleft -high phasic DA levels that might effectively activate D2 receptors and partially block D1 receptors simultaneously (Seamans and Yang, 2004) . This physiological action of DA may have been obstructed by the D2 antagonist.
Regarding 3, DA can have early or delayed effects on cortical neurons. Hence, the effect will depend on the time point at which measurements are taken. For layer V pyramidal cells in prefrontal cortex, Seamans and colleagues (2001) showed a biphasic dopaminergic modulation of neuronal activity: a fast-onset presynaptic D2-mediated depression of inhibitory post-synaptic currents (IPSC) was followed by a delayed, long-lasting and D1-mediated IPSC increase. A similar biphasic effect on excitatory postsynaptic potentials has been described for hippocampal CA1 pyramidal cells (fast-onset D2 mediated decrease followed by a delayed D1 induced increase, Gribkoff and Ashe, 1984; Huang and Kandel, 1995) . In our experimental time line we may have captured early D2-mediated effects only.
The fact that the D1-antagonist had no effect, could have been influenced by Ketamine anaesthesia. Ketamine is an N-methyl-D-aspartate (NMDA)-antagonist and reciprocal interactions between D1-receptors and NMDA-receptors have been reported. Activation of NMDA-receptors recruits D1-receptors from the interior of the cell to the plasma membrane (Scott et al., 2002) . Additionally, activation of D1-receptors increased NMDA-evoked currents in pyramidal neurons in PFC (Chen et al., 2004) . Hence, D1-receptor mediated enhancement of glutamatergic signalling might enhance excitability in cortical circuits.
Blocking NMDA-receptors with Ketamine could occlude this effect. However, using no anesthesia would produce unacceptable discomfort. Other anesthetics, e.g. barbiturates and gases like isoflurane, depress corticomotor evoked potentials even at low concentrations (Calancie et al., 1991; Chiba et al., 1998) . Propofol may be an alternative (Luft et al, 2001) but GABA-agonist effects and the need for repeated venous canulations reduce its value as compared with Ketamine. Ketamin plus Xylazine is known to produce little effects on CMEP amplitudes (Zandieh et al., 2003) .
Forelimb specific effects of D2 antagonist
The effects of D2 inhibition on representation size were found for wrist/elbow representations, which were closest to the injection site, but not for shoulder or hindlimb, likely reflecting the limited spread of the drug around the injection site consistent with previous findings (Luft et al., 2004) . In contrast, no joint specificity was found for stimulation threshold and latencies. This may be related to the fact that representation size is measured on a discrete scale while threshold and latency are continuous measures. If the concentration of the drug drops beyond a threshold, sudden cessation of its effect on a discrete measure is expected, while continuous parameters are gradually affected.
Modulation of M1 excitability by D2-receptors
In humans systemic application of DA-antagonists increases M1 excitability (Ziemann et al., 1997) . Similarly, Parkinson's disease (PD) patients in whom dopaminergic neurons degenerate, have increased M1 excitability (for review, Boroojerdi, 2002) . These results seem contrary to our findings. The discrepancy is most likely explained by the fact that DAantagonist were applied systemically affecting all dopaminergic system in the brain; these systems are also all affected by PD. Interfering with basal ganglia dopaminergic neurotransmission also affects cortex: Antagonization of striatal DA receptors stimulates excitatory thalamo-cortical projections thereby increasing cortical excitability (DeLong, 1990; Berardelli et al., 1996; Ziemann et al., 1997) .
D2 receptor activation potentially alters M1 excitability through different mechanisms:
(1) direct reduction of the excitability of primary motor neurons, (2) a depression of excitatory (glutamatergic) synaptic transmission, or (3) an increase in inhibitory (GABAergic) synaptic transmission.
Regarding 1, DA applied into M1 in wake cats lead to increased excitability during a conditioned placing response (Storozhuk et al., 1998 and . Similarly, in layer V of primate motor cortex, DA increased spontaneous activity in approximately 40% of the DA responsive neurons (Sawaguchi et al., 1986) . These findings are consistent with our observations. In contrast, Awenowicz and Porter (2002) described a reduction in excitability of motoneurons mediated through an activation of somatically located D1-and D2-receptors in rats (Awenowicz and Porter, 2002) . These conflicting results may be attributable to different experimental settings. In the latter study, iontophertical application of DA and its agonists/antagonistits in the immediate vicinity of the cell body was performed. Thus, given that DA receptors show an inhomogeneous subcellular distribution (Bergson et al., 1995) , a different subset of receptors may be activated/blocked than in our experiments where the drugs were delivered to the entire cell. Alternatively, as discussed above, application of exogenous DA at unphysiological doses may critically influence results, because the receptor subtype preference (D1 vs. D2) depends on DA concentrations (Trantham-Davidson et al., 2004) .
Regarding 2, in the monkey prefrontal and motor cortex (Goldman-Rakic et al., 1989) as well as the human temporal cortex (Smiley et al., 1992) , dopaminergic terminals have been shown to target dendritic spines and shafts in close proximity to excitatory synapses suggesting that DA modulates excitatory inputs. D2 receptors have been shown to reduce AMPA receptor mediated currents via presynaptic (CA1, rat; Otmakhova et al., 1999) and postsynaptic mechanisms (rat striatum and human cerebral cortex; Cepeda et al., 1992 and . D2 receptor dependent depression of NMDA receptor mediated currents has been observed in rat striatum, VTA and CA1 (Huang and Kandel, 1995; Hsu et al.,1995 ; Levine et al., 1996; Otmakhova et al., 1999; Koga and Momiyama, 2000) . In rat motor cortex, DA depresses activity of pyramidal tract neurons evoked by stimulation of transcallosal and thalamocortical afferents via D1 and D2 receptors (Huda et al., 1999 and . Hence, DA likely depresses excitatory synapses. D2 antagonization should have the opposite effect, hence, should enhance M1 excitability. Because this is contrary to our findings, the D2-mediated modulation of excitatory synapses cannot be assumed as an underlying mechanism here.
Regarding 3, in the frontal cortex of rodents and primates, dopaminergic terminals form synapses on dendrites of GABAergic cells (Sesack et al., 1995; Le Moine and Gaspar, 1998) . These neurons are fast-spiking interneurons containing the calcium binding protein parvalbumin ('basket-cells', Sesack et al., 1998; Porter et al., 2000; Gorelova et al., 2002) .
These interneurons exert a strong perisomatic inhibition thereby effectively controlling primary motor neuron excitability (Markram et al., 2004) . In the basal ganglia, D2 receptor activation decreases GABA release (Harsing and Zigmond, 1997 ) by a presynaptic mechanism (Cooper and Stanford, 2001; Momiyama and Koga, 2001) . In prefrontal cortex, results are heterogeneous (Sesack and Bunney, 1989; Seamans and Yang, 2004) . IPSPs measured in layer V PFC pyramidal neurons are depressed by D2 activation. This is mediated by a presynaptic reduction of transmitter release in fast-spiking interneurons as well as a direct postsynaptic modulation of GABA A receptors (Seamans et al., 2001; Gorrelova et al., 2002; Seamans and Yang, 2004) . If a similar mechanism exists in M1, blocking D2 receptors with raclopride should increase the inhibitory drive on M1 output neurons and reduce M1 excitability -in line with our findings. For PFC, Seamans and colleagues (2001) introduced a computational model to simulate the effects of D1 and D2 receptor activation on network activity. They describe a "D2-receptor-dominated" state defined by a net reduction in inhibition that allows for a preservation of activity that is thereby kept in the working memory buffer. Our findings suggest that this model may also be applicable to M1.
D2-receptor mediated increase in movement latencies
Manipulation of the balance between inhibition and excitation not only influences excitability and somatotopy (Jacobs and Donoghue, 1991) but may also affect movement latencies through desynchronization of intracortical signalling. Increased movement latencies have been described after blocking metabotropic glutamate receptors during a conditioned reaction in cats (Storozhuk et al., 2004) . This effect was reversed by DA application. Hence, D2 antagonization may interfere with these mechanisms thereby increasing latencies.
Functional implications for awake and behaving animals
Modulating M1 excitability, somatotopy and motor conduction time has an influence on motor function and movement learning (Pascual-Leone et al., 1995; Nudo et al., 1996; Monfils et al., 2005; Molina-Luna et al., 2008; Rioult-Pedotti et al., 2007; Pekanovic et al., 2007) . Training-induced enlargement of representations is necessary for successful motor learning (Conner et al., 2003) . In humans, motor learning is accompanied by an increase in M1-excitability (Pascual-Leone et al., 1995) . It therefore seems likely that D2-mediated effects on M1 have their physiological role in movement execution and/or learning.
In the dopaminergic projection between the ventral tegmental area (VTA) and the prefrontal cortex (PFC), DA is released in bursts as a response to appetitive or novel stimuli (Romo and Schultz, 1990) or as background tonic activity (Seamans and Yang, 2004) . This study cannot discern the effects of phasic versus tonic release on M1-excitability. However, the dopaminergic tone in PFC is negligible under anaesthetesia (Seamans and Yang, 2004) . If the same is true for M1, we have more likely affected phasic DA-release -possibly triggered by the electrical stimulation -than the tonic release.
Conclusion
Dopaminergic neurotransmission in M1 modulates cortical excitability and somatotopy.
This effect is mediated by D2 receptors and may be caused by dopaminergic modulation of GABAergic signalling. Through these effects, DA may serve to harmonize motor action patterns and possibly task-related muscle synergies to enable precise movements. In addition, it may play a role in movement learning. application of the D2 antagonist raclopride (0.5µl, 10µg/µl; n=6) reversibly increases stimulation thresholds of all joints. D1 antagonist SCH 23390 (0.5µl, 600ng/µl; n=6) and
